目的：系统评价国内外原发性肝癌（primary liver cancer，PLC）患者抑郁症状的发生率。方法：计算 机检索PubMed、Embase、The Cochrane Library、Web of Science、中国生物医学文献数据库、中国知网、万 方数据库和维普数据库，收集关于国内外PLC患者抑郁症状发生率的文献，检索时限为建库至2022年4 月。2名研究者独立筛选文献、提取资料并评价纳入文献的偏倚风险后，采用Stata 16.0软件进行Meta分 析。结果：共纳入20篇文献。Meta分析结果显示，国内外PLC患者抑郁症状的发生率为47.1%（95%CI 38.7%～55.5%）。亚组分析结果显示，研究地域为国内、年龄＜60岁、收入水平低、无工作、肿瘤分期为Ⅳ 期、治疗前、筛查工具为HADS的患者抑郁症状发生率更高。结论：PLC患者抑郁症状的发生率较高。

To systematically review the prevalence of depressive symptoms in patients with primary liver cancer (PLC) worldwide. Methods: PubMed, Embase, The Cochrane Library, Web of Science, China Biomedical Literature Database, CNKI, Wanfang database and VIP database were systematically searched to identify literature investigating the prevalence of depressive symptoms in PLC patients from the inception of these databases until April 2022. Two researchers independently screened the literature, extracted data, and evaluated the risk of bias in the included literature. Meta-analysis was performed using Stata 16.0 software. Results: A total of 20 literatures were included. Meta-analysis results showed that the prevalence of depressive symptoms in PLC patients was 47.1% (95%CI 38.7%～55.5% ). The results of subgroup analysis showed that higher rates of depression were observed in patients with the following characteristics: Chinese, < 60 years old, low income, unemployment, stage Ⅳ tumor, no treatment and assessment using the HADS screening tool. Conclusion: PLC patients had a high prevalence of depressive symptoms.